Effects of aleglitazar on cardiovascular risk factors in patients with stage 3 chronic kidney disease and type 2 diabetes

✍ Scribed by Herz, Matthias; Malmberg, Klas; Hanefeld, Markolf; Ruilope, Luis; Lincoff, A. Michael; Viberti, Giancarlo; Mudie, Nadejda; Urbanowska, Teresa; Reigner, Sylvie Meyer

• Book ID: 123205722
• Publisher: Elsevier Science
• Year: 2013
• Tongue: English
• Weight: 57 KB
• Volume: 231
• Category: Article
• ISSN: 0021-9150
• DOI: 10.1016/j.atherosclerosis.2013.07.015